PolyNovo share price falls 17% in two days after major insider selling

This medical device company has been hammered since its chairman sold shares.

The PolyNovo Ltd (ASX: PNV) share price has been having a tough week.

In morning trade, the medical device company's shares were down as much as 6% to $1.71.

When the PolyNovo share price hit that level, it was down over 17% in the space of two days.

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.

Image source: Getty Images

Why is the PolyNovo share price under pressure?

Investors have been hitting the sell button this week amid some major insider selling.

According to a change of director's interest notice, the company's chairman, David Williams, sold a large number of PolyNovo shares between 17 March to 22 March.

Williams sold a total of 4.75 million shares across this period for a total consideration of approximately $9.7 million. This equates to an average sale price of $2.04 per share.

Should you be concerned?

Insider selling rarely goes down well with the market. That's because it is often regarded as a bearish indicator.

After all, if you were so confident that the PolyNovo share price was good value and destined to head higher, you wouldn't be a seller.

But it is worth remembering that directors do have a life outside their company. And that is what has driven the sale of these shares.

PolyNovo explained that Williams needed the funds to support a US property purchase. It advised:

Chairman Mr David Williams has sold 4.75m shares, the proceeds of which will part settle a US property purchase.

The company also highlights that Williams still has a considerable holding following this sale and has no plans to offload any other shares in the near future. It adds:

Mr Williams still holds 21,384,432 fully paid ordinary shares and does not intend to sell more shares for the foreseeable future.

All in all, this appears to demonstrate that Williams' interests remain firmly aligned with shareholders, making this selloff probably a bit of an overreaction.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended PolyNovo. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »